Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 16/20 | 0.80 |
| ▸ | CDK4 | P11802 | 6/20 | 0.75 |
| ▸ | CDK1 | P06493 | 2/20 | 0.52 |
| ▸ | IKBKB | O14920 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4817051 | 0.95 | CDK2 (0.72) | CDK2CDK4CDK1IKBKB | |
| SCHEMBL4817291 | 0.92 | CDK2 (0.68) | CDK2CDK4CDK1IKBKB | |
| SCHEMBL4821591 | 0.91 | CDK2 (0.72) | CDK2CDK4CDK1IKBKB | |
| SCHEMBL6594955 | 0.89 | CDK2 (1.00) | CDK2CDK4CDK1IKBKB | |
| SCHEMBL4817036 | 0.86 | CDK2 (0.79) | CDK2CDK4CDK1IKBKB | |
| SCHEMBL4824463 | 0.86 | CDK2 (0.58) | CDK2CDK4CDK1IKBKB | |
| SCHEMBL5092316 | 0.85 | CDK2 (1.00) | CDK2CDK4CDK1 | |
| SCHEMBL4824472 | 0.83 | CDK2 (0.63) | CDK2CDK4CDK1IKBKB | |
| SCHEMBL6599298 | 0.82 | CDK2 (0.67) | CDK2CDK4CDK1IKBKB | |
| SCHEMBL4855523 | 0.82 | CDK2 (0.83) | CDK2CDK4CDK1IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7446105-B2 | Pyrimidine compounds | ASTRAZENECA AB (SE) | 2008-11-04 | — | — | US | claimed |
| US-20050119291-A1 | Pyrimidine compounds | ASTRAZENECA AB (SE) | 2005-06-02 | — | — | US | claimed |
| EP-1485374-A1 | PYRIMIDINE COMPOUNDS | AstraZeneca AB (SE) | 2004-12-15 | — | — | EP | claimed |
| WO-2003076433-A1 | PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2003-09-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119291-A1 | Pyrimidine compounds | TYMP, TYMS, CCNT1 | CDK2 22/4885CDK4 47/4885CDK1 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.